Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry†

被引：6

作者：

Obr, Ales ^{[1
,2
]}

Prochazka, Vit ^{[1
,2
]}

Papajik, Tomas ^{[1
,2
]}

Klener, Pavel, Jr. ^{[3
,4
]}

Janikova, Andrea ^{[5
]}

Salek, David ^{[5
]}

Belada, David ^{[6
,7
]}

Pytlik, Robert ^{[8
]}

Sykorova, Alice ^{[6
,7
]}

Mocikova, Heidi ^{[9
,10
]}

Simkovic, Martin ^{[6
,7
]}

Campr, Vit ^{[11
]}

Dlouha, Jitka ^{[4
,12
,13
]}

Furst, Tomas ^{[14
]}

Trneny, Marek ^{[3
,4
]}

机构：

[1] Palacky Univ, Fac Med & Dent, Dept Hematooncol, Olomouc, Czech Republic

[2] Univ Hosp, Olomouc, Czech Republic

[3] Fac Med 1, Dept Hematol, Dept Internal Med 1, Prague, Czech Republic

[4] Gen Teaching Hosp, Prague, Czech Republic

[5] Univ Hosp, Dept Hematol & Oncol, Brno, Czech Republic

[6] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[7] Fac Med, Hradec Kralove, Czech Republic

[8] Inst Hematol & Blood Transfus, Prague, Czech Republic

[9] Charles Univ Prague, Fac Hosp Kralovske Vinohrady, Dept Internal Med & Haematol, Prague, Czech Republic

[10] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[11] Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic

[12] Fac Med 2, Prague, Czech Republic

[13] Fac Med 1, Dept Hematol, Dept Internal Med 1, Data Management Off, Prague, Czech Republic

[14] Palacky Univ, Fac Sci, Dept Math Anal & Applicat Math, Olomouc, Czech Republic

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 03期

关键词：

Mantle cell lymphoma; chemotherapy; maintenance; rituximab; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; FOLLICULAR LYMPHOMA; OLDER PATIENTS; OPEN-LABEL; IMMUNOCHEMOTHERAPY; TRANSPLANTATION; IMPROVES; CHOP; MULTICENTER;

D O I：

10.1080/10428194.2018.1508672

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analyzed 495 MCL patients from the Czech Lymphoma Study Group data registry. With the median follow-up of 4.4 years, 51.7% patients progressed or relapsed and 34.1% died. Five-year overall survival reached 65.3% and five-year progression free survival 44.1% of the patients. Maintenance rituximab (MR) after first line therapy improved overall and progression free survival compared to the patients under observation only (both p < .001). Elevated beta-2-microglobulin (p = .003), presence of systemic symptoms (p = .002), ECOG >0 (p = .003), age (p = .014), and MIPI (p < .001) were associated with MR failure. Patients who did not achieve complete remission have had two-fold higher risk of MR failure (p < .001). Autologous stem cell transplant reduced the risk of MR failure by 69% (p < .001). The MIPI and the beta-2-microglobulin were identified as independent predictors of MR failure (p = .02 and p = .03, respectively). Patients who relapsed/progressed on MR reached shorter OS calculated from the MR start compared to patients without failure (HR = 15.0; p < .001).

引用

页码：748 / 755

页数：8

共 25 条

[1]

[Anonymous], 2007, KLIN ONKOL

[2] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[3] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[4]

Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx289, 10.1093/annonc/mdx223]

[5] Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group [J].

Geisler, Christian H. ;

Kolstad, Arne ;

Laurell, Anna ;

Andersen, Niels S. ;

Pedersen, Lone B. ;

Jerkeman, Mats ;

Eriksson, Mikael ;

Nordstrom, Marie ;

Kimby, Eva ;

Boesen, Anne Marie ;

Kuittinen, Outi ;

Lauritzsen, Grete F. ;

Nilsson-Ehle, Herman ;

Ralfkiaer, Elisabeth ;

Akerman, Mans ;

Ehinger, Mats ;

Sundstrom, Christer ;

Langholm, Ruth ;

Delabie, Jan ;

Karjalainen-Lindsberg, Marja-Liisa ;

Brown, Peter ;

Elonen, Erkki .

BLOOD, 2008, 112 (07) :2687-2693

[6] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

[7] Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network [J].

Hermine, Olivier ;

Hoster, Eva ;

Walewski, Jan ;

Bosly, Andre ;

Stilgenbauer, Stephan ;

Thieblemont, Catherine ;

Szymczyk, Michal ;

Bouabdallah, Reda ;

Kneba, Michael ;

Hallek, Michael ;

Salles, Gilles ;

Feugier, Pierre ;

Ribrag, Vincent ;

Birkmann, Josef ;

Forstpointner, Roswitha ;

Haioun, Corinne ;

Haenel, Mathias ;

Casasnovas, Rene Olivier ;

Finke, Juergen ;

Peter, Norma ;

Bouabdallah, Kamal ;

Sebban, Catherine ;

Fischer, Thomas ;

Duehrsen, Ulrich ;

Metzner, Bernd ;

Maschmeyer, Georg ;

Kanz, Lothar ;

Schmidt, Christian ;

Delarue, Richard ;

Brousse, Nicole ;

Klapper, Wolfram ;

Macintyre, Elizabeth ;

Delfau-Larue, Marie-Helene ;

Pott, Christiane ;

Hiddemann, Wolfgang ;

Unterhalt, Michael ;

Dreyling, Martin .

LANCET, 2016, 388 (10044) :565-575

[8] Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma [J].

Herrmann, Annina ;

Hoster, Eva ;

Zwingers, Thomas ;

Brittinger, Guenter ;

Engelhard, Marianne ;

Meusers, Peter ;

Reiser, Marcel ;

Forstpointner, Roswitha ;

Metzner, Bernd ;

Peter, Norma ;

Woermann, Bernhard ;

Truemper, Lorenz ;

Pfreundschuh, Michael ;

Einsele, Hermann ;

Hiddemann, Wolfgang ;

Unterhalt, Michael ;

Dreyling, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :511-518

[9]

Hoster E., 2009, BLOOD, V114, P880, DOI [10.1182/blood.V114.22.880.880, DOI 10.1182/BLOOD.V114.22.880.880]

[10] A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [J].

Hoster, Eva ;

Dreyling, Martin ;

Klapper, Wolfram ;

Gisselbrecht, Christian ;

van Hoof, Achiel ;

Kluin-Nelemans, Hanneke C. ;

Pfreundschuh, Michael ;

Reiser, Marcel ;

Metzner, Bernd ;

Einsele, Hermann ;

Peter, Norma ;

Jung, Wolfram ;

Woermann, Bernhard ;

Ludwig, Wolf-Dieter ;

Duehrsen, Ulrich ;

Eimermacher, Hartmut ;

Wandt, Hannes ;

Hasford, Joerg ;

Hiddemann, Wolfgang ;

Unterhalt, Michael .

BLOOD, 2008, 111 (02) :558-565

← 1 2 3 →